MSS - Latest News

Maison Solutions Inc. Class A Common Stock (MSS), operates in Consumer Defensive / Grocery Stores, trades on NASDAQ.

Market capitalization stands near $1.3M. Beta to the broader market is 4.03.

The article list below shows the most recent MSS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent MSS Headlines

Head to Head Contrast: US Foods (NYSE:USFD) & Maison Solutions (NASDAQ:MSS)

defenseworld.net - Oct 11, 2026

US Foods (NYSE: USFD - Get Free Report) and Maison Solutions (NASDAQ: MSS - Get Free Report) are both consumer staples companies, but which is the bet

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

gurufocus.com - Oct 2, 2026

[url="]Agenus Inc.

Maison Solutions Inc. Receives Additional Nasdaq Notification Regarding Delayed Filing of Quarterly Report on Form 10-Q

accessnewswire.com - Sep 29, 2026

MONTEREY PARK, CA / ACCESS Newswire / September 29, 2026 / Maison Solutions Inc. (Nasdaq:MSS) (the "Company") today announced that, on September 23,

Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study

globenewswire.com - Sep 28, 2026

Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study Company expects to have sufficient Part

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

prnewswire.com - Sep 1, 2026

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Drivi

How News Affects MSS Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track MSS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked MSS news questions

What is the latest MSS news headline?

The most recent MSS headline (Oct 11, 2026) is "Head to Head Contrast: US Foods (NYSE:USFD) & Maison Solutions (NASDAQ:MSS)". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the MSS news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What MSS news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual MSS options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.